Traders Purchase Large Volume of Compass Pathways Call Options (NASDAQ:CMPS)

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) was the recipient of some unusual options trading on Monday. Investors acquired 8,121 call options on the stock. This represents an increase of approximately 81% compared to the average daily volume of 4,494 call options.

Compass Pathways News Roundup

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and $70 price target on Compass Pathways while lifting multiple earnings estimates for 2026 and 2027, signaling continued optimism about the company’s longer-term outlook.
• Positive Sentiment: The firm improved its Q2 2026, Q3 2026, Q4 2026, Q1 2027, Q2 2027, Q3 2027, Q4 2027, FY2026 and FY2027 EPS forecasts, which can reinforce the bullish case for CMPS if investors view the revisions as evidence of improving fundamentals.
• Positive Sentiment: Trading activity also picked up, with unusual call option buying on Compass Pathways—often a sign that traders are positioning for a sharp move higher ahead of a potential catalyst.
• Positive Sentiment: Recent media coverage highlighted that retail traders believe a major FDA catalyst may be developing, adding to speculation around the stock and helping explain why shares have been strengthening. CMPS stock is breaking out again — retail traders think a major FDA catalyst is brewing
• Neutral Sentiment: Another article described CMPS as a momentum-driven psychedelics stock that continues to attract attention, but it did not add a new company-specific development beyond the ongoing speculation. This psychedelics stock just keeps getting hotter; why shares bypassed a profit-taking zone
• Negative Sentiment: Lifesci Capital reportedly cut earnings estimates for Compass Pathways, which is a reminder that not all analysts are turning more bullish on near-term profitability.

Wall Street Analyst Weigh In

Several analysts recently weighed in on CMPS shares. Maxim Group increased their target price on Compass Pathways from $12.00 to $20.00 and gave the company a “buy” rating in a research note on Friday. Wall Street Zen upgraded Compass Pathways from a “strong sell” rating to a “hold” rating in a research note on Saturday. Canaccord Genuity Group decreased their target price on Compass Pathways from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, March 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Pathways in a research note on Monday, April 20th. Finally, Compass Point set a $15.00 target price on Compass Pathways in a research note on Thursday, February 12th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $20.58.

Hedge Funds Weigh In On Compass Pathways

Several hedge funds and other institutional investors have recently modified their holdings of CMPS. Corient Private Wealth LLC increased its holdings in Compass Pathways by 3.2% during the 4th quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock valued at $265,000 after purchasing an additional 1,200 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in Compass Pathways by 67.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after purchasing an additional 1,920 shares in the last quarter. CWM LLC increased its holdings in Compass Pathways by 19.2% during the 3rd quarter. CWM LLC now owns 15,650 shares of the company’s stock valued at $90,000 after purchasing an additional 2,525 shares in the last quarter. Conservest Capital Advisors Inc. increased its holdings in Compass Pathways by 24.6% during the 4th quarter. Conservest Capital Advisors Inc. now owns 25,363 shares of the company’s stock valued at $175,000 after purchasing an additional 5,000 shares in the last quarter. Finally, Persistent Asset Partners Ltd acquired a new stake in Compass Pathways during the 4th quarter valued at $38,000. Institutional investors own 46.19% of the company’s stock.

Compass Pathways Price Performance

Compass Pathways stock opened at $10.56 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.32 and a quick ratio of 3.32. The company has a market capitalization of $1.43 billion, a PE ratio of -3.35 and a beta of 2.39. Compass Pathways has a one year low of $2.25 and a one year high of $11.65. The business has a 50 day simple moving average of $7.30 and a 200 day simple moving average of $6.77.

Compass Pathways (NASDAQ:CMPS) last posted its earnings results on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.15. On average, sell-side analysts forecast that Compass Pathways will post -0.99 EPS for the current fiscal year.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.